Professional Services Advanced Molecular Testing | TN, USA

Proven Industry Leadership

Jamie Platt PhD, MB (ASCP)

CEO & Founder

Jamie Platt has more than 15 Years of Leadership in Next Generation Sequencing and Clinical Diagnostics. She has propelled and directed a global $4.7B Fortune 500 diagnostics provider into the emerging genomics market through adoption of NGS technology; Spearheaded the development & validation of the first NGS-based HIV test for a large commercial reference lab (secured NYS approval) and increased revenue by $1M within 6 months of launch. Jamie has a strong track record of building NGS-based Genomics programs with FDA-aligned, design control development QMS and ISO 15189 readiness for growth from clinical into Pharma services markets.

Assay Development and Validation
Commercialization
High-Complexity Molecular Testing
Emerging Technology Market Assessment
Implementation of New Technologies in Clinical Diagnostics
Clinical Trials for Pharma and Device Manufacturers
Genomics program development and pipeline strategies
Strategic development and M & A’s

Linked-In Profile

Selected Peer Reviewed Publications

CLSI.Nucleic Acid Sequencing Methods in Diagnostic Laboratory Medicine; Approved Guideline – Second Edition.CLSI document MM09-A2. Wayne, PA. Clinical and Laboratory Standards Institute; 2014.
Development and Validation of a Next-Generation Sequencing Assay for and Variants for the Clinical Laboratory. 2015. PLoS ONE 10(8): e0136419. doi:10.1371/journal.pone.0136419
Comparison of Genotypic and Phenotypic HIV Type 1 Tropism Assay: Results from the Screening Samples of Cenicriviron Study 202, a Randomized Phase II Trial in Treatment-Naïve Subjects. AIDS Research and Human Retroviruses. February 2014, 30(2): 151-159. doi:10.1089/aid.2013.0123.
A Genotypic Test for HIV-1 Tropism Combining Sanger Sequencing with Ultradeep Sequencing Predicts Virologic Response in Treatment-Experienced Patients. 2012. PLoS ONE 7(9): e46334. doi:10.1371/journal.pone.0046334

Network of Industry Professionals

Bridgenomics has access to over 2,500+ professional network of KOLs, leaders, development scientists, end users, and investors. Including:

High-complexity CLIA Lab Directors (ABMGG, HCLD(ABB), ABMM, ABMLI)
Medical Directors with NGS experience
Quality Specialists and Regulatory Experts (ASQ CQPA and others)
Licensed, NGS-experienced Medical Technologists, including California (CGMBS)
Field Application Specialists and Molecular Assay Development Scientists (including PhDs)
Experienced Bioinformaticians, Linux gurus, and IT Security Experts
Six Sigma Black Belts and Lean for Six Sigma and Design for Six Sigma experts
Medical writers and marketing experts